

# CITATION REPORT

List of articles citing

A listing of human tumor antigens recognized by T cells

DOI: 10.1007/s002620000169

Cancer Immunology, Immunotherapy, 2001, 50, 3-15.

**Source:** <https://exaly.com/paper-pdf/32881835/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
374	Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. <b>1992</b> , 34, 529		1
373	Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. <b>1992</b> , 33, 433		
372	Tumour cell-based vaccines for the treatment of melanoma. <b>2001</b> , 15, 713-20		3
371	Vaccination with T Cell-Defined Antigens: Biological Basis and Clinical Applications. <b>2001</b> , 87, 10-10		
370	Use of Human Recombinant Antibodies to the Marker of Angiogenesis Ed-B in Cancer Therapy. <b>2001</b> , 87, 8-10		1
369	Immunotherapy of melanoma. <b>2001</b> , 104, 1-7		14
368	From tumor antigens to immunotherapy. <b>2001</b> , 6, 163-70		17
367	Cellular vaccine therapy for cancer. <i>Expert Review of Vaccines</i> , <b>2002</b> , 1, 303-16	5.2	5
366	Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. <b>2002</b> , 169, 6036-47		66
365	Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes. <b>2002</b> , 169, 2988-96		11
364	Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. <b>2002</b> , 169, 4399-407		44
363	BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. <b>2002</b> , 99, 6806-11		279
362	Immunotherapy of colorectal cancer. <b>2002</b> , 64, 181-200		9
361	Advances in the non-surgical treatment of melanoma. <b>2002</b> , 11, 75-85		12
360	Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. <b>2002</b> , 20, 4181-90		117
359	Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. <b>2002</b> , 99, 9421-6		85
358	Identification of tumor-associated antigens using proteomics. <b>2002</b> , 1, 257-62		31

357	DNA-based tumor vaccines. <b>2002</b> , 25, 528-32		1
356	Tissue Microarray Evaluation of Melanoma Antigen E (MAGE) Tumor-Associated Antigen Expression. <i>Annals of Surgery</i> , <b>2002</b> , 236, 785-793	7.8	52
355	ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. <b>2002</b> , 99, 2100-6		76
354	Immunohistochemical Detection of Melanoma Antigen E (MAGE) Expression in Breast Carcinoma. <b>2002</b> , 1, 471-476		
353	A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , <b>2002</b> , 25, 243-251	5	297
352	Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. <b>2002</b> , 94, 805-18		335
351	Challenges in the development of effective peptide vaccines for cancer. <b>2002</b> , 77, 339-49		44
350	Immunotherapy for pancreatic cancer: current concepts. <b>2002</b> , 16, 159-97, viii		17
349	. <b>2002</b> ,		5
348	Vaccine Therapy of Cancer. <b>2002</b> , 1, S28-S28		
347	Towards defining specific antigens for cutaneous lymphomas. <b>2002</b> , 25, 448-54		5
346	Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients. <i>Journal of Immunological Methods</i> , <b>2002</b> , 266, 87-103 <sup>5</sup>		15
345	The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. <b>2002</b> , 12, 399-414		208
344	Search for Universal Tumor-Associated T Cell Epitopes. <b>2002</b> , 1-16		
343	Hybrid Cell Vaccination for Cancer Immune Therapy. <b>2002</b> , 230-252		
342	Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines. <b>2002</b> , 98, 57-62		11
341	Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. <b>2002</b> , 100, 702-5		61
340	Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. <i>Tissue Antigens</i> , <b>2002</b> , 59, 273-9		6

339	Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. <b>2002</b> , 188, 22-32	646
338	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. <b>2002</b> , 188, 81-96	132
337	Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. <b>2002</b> , 188, 97-113	215
336	The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. <b>2002</b> , 188, 155-63	21
335	Towards patient-specific tumor antigen selection for vaccination. <b>2002</b> , 188, 164-76	61
334	All in the head: obstacles for immune rejection of brain tumours. <b>2002</b> , 107, 28-38	51
333	Immunology of the peritoneal cavity: relevance for host-tumor relation. <b>2002</b> , 12, 3-17	50
332	The future of vaccination as a treatment strategy in dermatological diseases. <b>2002</b> , 27, 608-13	1
331	Die Zukunft von Impfungen als Therapiestrategie bei dermatologischen Erkrankungen. <b>2002</b> , 77, 685-690	
330	The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies. <b>2002</b> , 26, 1113-8	13
329	Identification of tumour-associated T-cell epitopes for vaccine development. <b>2002</b> , 2, 514-20	111
328	Mimotopes of tumor-associated T-cell epitopes for cancer vaccines determined with combinatorial peptide libraries. <b>2003</b> , 25, 53-61	7
327	Biochemical determination of natural tumor-associated T-cell epitopes. <b>2003</b> , 25, 71-8	7
326	Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. <i>Cancer Immunology, Immunotherapy</i> , <b>2003</b> , 52, 455-62	7-4 33
325	What's new in the field of cancer vaccines?. <b>2003</b> , 60, 1296-310	17
324	Target molecules in specific immunotherapy against prostate cancer. <b>2003</b> , 8, 193-9	26
323	Tumour immunology, vaccination and escape strategies. <b>2003</b> , 30, 177-83	42
322	Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. <b>2003</b> , 1653, 61-71	14

321	Immunotherapy of melanoma. <b>2003</b> , 13, 391-400	43
320	Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. <b>2003</b> , 13, 409-15	89
319	Rational peptide-based tumour vaccine development and T cell monitoring. <b>2003</b> , 13, 423-9	31
318	Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. <b>2003</b> , 13, 449-59	63
317	A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma. <b>2003</b> , 104, 362-8	12
316	Cancer/testis-associated genes: identification, expression profile, and putative function. <b>2003</b> , 194, 272-88	220
315	NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. <b>2003</b> , 33, 2033-43	56
314	Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. <b>2003</b> , 16, 324-32	49
313	Making use of the primary tumour. <b>2003</b> , 25, 79-86	6
312	Natural mechanisms protecting against cancer. <b>2003</b> , 90, 103-22	142
311	Immunology and immunotherapy of colorectal cancer. <b>2003</b> , 46, 33-57	104
310	cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. <b>2003</b> , 121, 198-206	42
309	Adjuvant therapy for high-risk primary and resected metastatic melanoma. <b>2003</b> , 33, 33-43	25
308	Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients. <b>2003</b> , 149, 282-8	13
307	Tumour-associated antigens in multiple myeloma. <b>2003</b> , 120, 3-9	25
306	Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?. <b>2003</b> , 22, 6564-9	41
305	Adoptive-cell-transfer therapy for the treatment of patients with cancer. <b>2003</b> , 3, 666-75	526
304	Allogeneic breast cancer cell vaccines. <b>2003</b> , 3 Suppl 4, S173-80	13

303	Epitope prediction algorithms for peptide-based vaccine design.	9
302	Growth and functional reactivity of lymphocytes obtained from three anatomic compartments in patients with non-small-cell lung cancer (NSCLC). <b>2003</b> , 18, 735-49	6
301	Genetic engineering of T cell specificity for immunotherapy of cancer. <b>2003</b> , 64, 56-68	52
300	Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. <b>2003</b> , 21, 781-6	29
299	T-cell immune responses in the brain and their relevance for cerebral malignancies. <b>2003</b> , 42, 97-122	66
298	Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. <b>2003</b> , 4, 104-9	84
297	22. Immune responses to malignancies. <b>2003</b> , 111, S677-86	23
296	ALK a novel lymphoma-associated tumor antigen for vaccination strategies. <b>2003</b> , 44, 1675-81	20
295	Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. <b>2003</b> , 171, 2197-207	48
294	Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. <b>2003</b> , 2, 388-98	38
293	Vaccination of patients with solid tumours. <b>2003</b> , 14, 817-24	27
292	Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. <b>2003</b> , 170, 1209-17	42
291	Rational approaches to human cancer immunotherapy. <b>2003</b> , 73, 3-29	93
290	Melacine: an allogeneic melanoma tumor cell lysate vaccine. <i>Expert Review of Vaccines</i> , <b>2003</b> , 2, 353-68 5.2	38
289	Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. <b>2003</b> , 14, 1497-510	78
288	Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. <b>2003</b> , 170, 2186-94	123
287	Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. <b>2003</b> , 170, 4349-61	57
286	Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. <b>2003</b> , 170, 6363-70	45

285	Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. <b>2003</b> , 171, 5172-9		16
284	Similar immune responses and antitumor effects of murine dendritic cells loaded with either exogenous or endogenous-synthesized protein. <b>2003</b> , 23, 1747		
283	Shifting gene expression profiles during ex vivo culture of renal tumor cells: implications for cancer immunotherapy. <b>2003</b> , 14, 133-45		5
282	Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. <b>2004</b> , 15, 393-404		58
281	Principles of Molecular Oncology. <b>2004</b> ,		6
280	Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. <b>2004</b> , 3, 891-8		9
279	Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. <b>2004</b> , 96, 1611-9		51
278	Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. <b>2004</b> , 101, 9051-6		32
277	Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. <b>2004</b> , 133, 179-97		17
276	T-cell epitope peptide vaccines. <i>Expert Review of Vaccines</i> , <b>2004</b> , 3, 563-75	5.2	17
275	MHC class I down-regulation: tumour escape from immune surveillance? (Review). <b>2004</b> , 25, 487		20
274	p53-based immunotherapy of cancer. Approaches to reversing unresponsiveness to T lymphocytes and preventing tumor escape. <b>2005</b> , 62, 134-50		2
273	A nonclassical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor. <b>2004</b> , 173, 4394-401		23
272	Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. <b>2004</b> , 101, 9363-8		77
271	Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. <b>2004</b> , 172, 3462-8		24
270	Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. <i>British Journal of Cancer</i> , <b>2004</b> , 90, 263-9	8.7	20
269	Vaccination as a treatment for breast or ovarian cancer. <i>Expert Review of Vaccines</i> , <b>2004</b> , 3, 269-77	5.2	5
268	Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. <b>2004</b> , 199, 155-66		293

267	Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6047-57	12.9	35
266	Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. <b>2004</b> , 4, 151-61		24
265	Immunotherapy dispenses with tumor antigens. <b>2004</b> , 22, 1096-8		10
264	Finding enzymatic gold on silver surfaces. <b>2004</b> , 22, 1098-9		3
263	Self-representation in the thymus: an extended view. <i>Nature Reviews Immunology</i> , <b>2004</b> , 4, 688-98	36.5	288
262	Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 287-96	8.7	20
261	MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 398-407	8.7	17
260	A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. <i>Journal of Immunological Methods</i> , <b>2004</b> , 291, 51-62	2.5	29
259	Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. <b>2004</b> , 11, 892-9		18
258	Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. <b>2004</b> , 21, 1018-25		41
257	Clinical applications of dendritic cell vaccination in the treatment of cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 275-306	7.4	120
256	Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 315-22	7.4	15
255	Identification of tumor antigens and T-cell epitopes, and its clinical application. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 196-203	7.4	30
254	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 227-33	7.4	108
253	The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 904-10	7.4	212
252	Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 935-45	7.4	25
251	The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 855-64	7.4	57
250	NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. <b>2004</b> , 54, 95-100		38



249	Allogeneic stem cell transplantation for the treatment of advanced solid tumors. <b>2004</b> , 26, 95-108	17
248	Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. <b>2004</b> , 110, 730-40	57
247	Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. <b>2004</b> , 200, 272-6	6
246	Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I. <b>2004</b> , 16, 356-65	2
245	Colorectal cancer vaccines: principles, results, and perspectives. <b>2004</b> , 127, 1821-37	26
244	Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. <b>2004</b> , 114, 1463-70	95
243	Interrelationship of Tumour and Immune System. <b>2004</b> , 391-398	
242	T-cell clonotypes in cancer. <b>2004</b> , 2, 11	16
241	Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. <b>2004</b> , 208, 197-206	23
240	Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro. <b>2004</b> , 211, 219-25	5
239	Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy. <b>2004</b> , 317, 1089-95	9
238	On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. <b>2004</b> , 23, 97-113	49
237	MAGE antigens: therapeutic targets in hepatocellular carcinoma?. <b>2004</b> , 40, 155-8	2
236	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma. <b>2004</b> , 40, 102-9	58
235	Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers. <i>Oncology Reports</i> , <b>2004</b> , 12, 275	3.5 3
234	Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. <i>Journal of Immunotherapy</i> , <b>2004</b> , 27, 265-72	5 67
233	Competition among peptides in melanoma vaccines for binding to MHC molecules. <i>Journal of Immunotherapy</i> , <b>2004</b> , 27, 425-31	5 13
232	Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. <b>2004</b> , 103, 3122-30	89

231	Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. <i>Journal of Immunotherapy</i> , <b>2005</b> , 28, 535-41	5	33
230	Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen. <i>Annals of Surgery</i> , <b>2005</b> , 242, 851-7, discussion 858	7.8	34
229	Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. <i>Journal of Immunotherapy</i> , <b>2005</b> , 28, 53-62	5	167
228	Immunogenicity of Bcl-2 in patients with cancer. <b>2005</b> , 105, 728-34		54
227	Immunotherapy of cancer through targeting of minor histocompatibility antigens. <b>2005</b> , 17, 202-10		75
226	Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma. <b>2005</b> , 95, 421-4		1
225	Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. <i>Cancer Science</i> , <b>2005</b> , 96, 498-506	6.9	37
224	Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587. <b>2005</b> , 140, 310-9		21
223	Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens. <b>2005</b> , 142, 454-60		22
222	Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes. <b>2005</b> , 12, 552-9		6
221	Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. <b>2005</b> , 204, 522-31		241
220	Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody. <b>2005</b> , 35, 2864-75		20
219	Impact of p53-based immunization on primary chemically-induced tumors. <b>2005</b> , 113, 961-70		11
218	Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. <b>2005</b> , 114, 936-41		16
217	Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 219-28	7.4	14
216	Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 359-71	7.4	33
215	Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 826-36	7.4	62
214	Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 867-79	7.4	14

213	Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 1180-90	7.4	72
212	Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation. <b>2005</b> , 29, 692-9		12
211	Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing. <b>2005</b> , 83, 420-8		9
210	New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients. <b>2005</b> , 62, 233-42		13
209	Cancer vaccines: the challenge of developing an ideal tumor killing system. <b>2005</b> , 10, 2285-305		13
208	Lipid-protamine-DNA-mediated antigen delivery. <b>2005</b> , 2, 401-6		28
207	Protective immunity against disparate tumors is mediated by a nonpolymorphic MHC class I molecule. <b>2005</b> , 174, 5367-74		15
206	Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3869-78	12.9	30
205	Proteomics in cancer vaccine development. <b>2005</b> , 2, 229-41		8
204	Analysis of T-cell receptor V beta gene repertoires after immune stimulation and in malignancy by use of padlock probes and microarrays. <b>2005</b> , 51, 768-75		22
203	Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. <b>2005</b> , 9, 515-32		16
202	Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression. <b>2005</b> , 19, 1513-5		24
201	T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. <b>2005</b> , 174, 7853-8		56
200	Tumor Immunology and Cancer Vaccines. <b>2005</b> ,		2
199	Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. <i>Cancer Research</i> , <b>2005</b> , 65, 2207-15	10.1	116
198	Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4545-52	12.9	43
197	Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6933-43	12.9	37
196	T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy. <b>2005</b> , 5, 523-36		14

- 195 Malignant melanoma--clinical development of peptide-based melanoma vaccines. **2006**, 39, 171-180
- 194 Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer. **2005**, 27, 1371
- 193 Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis. **2005**, 93, 129-58 11
- 192 Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. **2005**, 5, 1183-92 11
- 191 Cytotoxicity Assays. **2005**, 103-121
- 190 A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. **2005**, 346, 1299-311 20
- 189 Strategies to enhance the therapeutic efficacy of autologous hematopoietic stem cell transplantation by posttransplantation adoptive transfer of T cells with engineered graft-versus-tumor activity. **2005**, 11, 34-9 3
- 188 A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients. **2005**, 41, 1323-30 8
- 187 Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. **2005**, 23, 5572-82 21
- 186 HLA class I and II genotype of the NCI-60 cell lines. **2005**, 3, 11 43
- 185 Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. **2005**, 3, 4 37
- 184 CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma. **2005**, 3, 41 2
- 183 Tumor antigens and tumor antigen discovery. *Cancer Treatment and Research*, **2005**, 123, 89-111 3,5 28
- 182 Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. *Expert Review of Vaccines*, **2005**, 4, 315-27 5,2 11
- 181 Cancer immunity. **2005**, 129-148
- 180 Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. **2006**, 3, 8 9
- 179 Target Discovery and Validation Reviews and Protocols. **2006**,
- 178 Cancer Drug Resistance. **2006**, 17

177	A central role for central tolerance. <b>2006</b> , 24, 571-606		566
176	Effect of IL-1 on the hydrolysis of the tumor antigen epitope gp100(280-288) by fibroblast-expressed enzymes. <b>2006</b> , 36, 189-98		2
175	Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. <b>2006</b> , 211, 11-27		15
174	Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. <b>2006</b> , 211, 677-85		26
173	Tumor antigen targets and tumor immunotherapy. <b>2006</b> , 11, 337-43		10
172	Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes. <b>2006</b> , 19, 853-70		21
171	Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells. <b>2006</b> , 213-233		
170	Tumor-Reactive T-Cells for Adoptive Immunotherapy. <b>2006</b> , 167-179		
169	CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. <b>2006</b> , 107, 2786-9		57
168	Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. <i>Journal of Immunotherapy</i> , <b>2006</b> , 29, 472-6	5	23
167	Influence of p53 on anti-tumor immunity (Review). <b>2006</b> , 28, 519		
166	Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients. <b>2006</b> , 29, 577		0
165	Identification of melanoma-specific peptide epitopes by HLA-A2.1-restricted cytotoxic T lymphocytes. <b>2006</b> , 38, 110-8		2
164	Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. <i>Cancer Science</i> , <b>2006</b> , 97, 411-9	6.9	31
163	Cytotoxic T cells. <b>2006</b> , 126, 32-41		235
162	DNA vaccines for cancer too. <i>Cancer Immunology, Immunotherapy</i> , <b>2006</b> , 55, 119-30	7.4	24
161	Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , <b>2006</b> , 55, 495-502	7.4	15
160	The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. <i>Cancer Immunology, Immunotherapy</i> , <b>2006</b> , 55, 277-88	7.4	12

159	Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. <i>Cancer Immunology, Immunotherapy</i> , <b>2006</b> , 55, 933-47	7.4	6
158	Dendritic cell-based cancer immunotherapy targeting MUC-1. <i>Cancer Immunology, Immunotherapy</i> , <b>2006</b> , 55, 63-7	7.4	55
157	An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 319-29	7.4	33
156	Model of stimulation-responsive splicing and strategies in identification of immunogenic isoforms of tumor antigens and autoantigens. <b>2006</b> , 121, 121-33		21
155	Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. <b>2006</b> , 106, 890-9		42
154	Identification of tumor antigens by using proteomics. <b>2007</b> , 360, 327-34		4
153	Tumor antigens as surrogate markers and targets for therapy and vaccines. <b>2007</b> , 96, 175-90		16
152	Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1325-32	12.9	19
151	Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5801-8	12.9	50
150	A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. <b>2006</b> , 1, 805-823		2
149	Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. <i>Cancer Research</i> , <b>2006</b> , 66, 5910-8	10.1	193
148	Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 566-575	12.9	120
147	Identification of HLA-CW3, GNAS and IMPA as cytotoxic T-lymphocyte (CTL) target antigens using an allogeneic mixed lymphocyte tumor cell culture (MLTC) system and subsequent cDNA library screening. <b>2007</b> , 22, 206-22		1
146	Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 1648-54	8.7	14
145	Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. <b>2007</b> , 3, 8-13		54
144	Less yin, more yang: confronting the barriers to cancer immunotherapy. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5250-5	12.9	54
143	Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. <b>2007</b> , 21, 2173-84		11
142	An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. <i>Cancer Research</i> , <b>2007</b> , 67, 11309-16	10.16	20

141	Heightened risk of breast cancer following pregnancy: could lasting systemic immune alterations contribute?. <b>2007</b> , 16, 1082-6		20
140	In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells. <b>2007</b> , 3, 57-75		3
139	The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. <b>2007</b> , 6, 2081-91		39
138	Facilitating matched pairing and expression of TCR chains introduced into human T cells. <b>2007</b> , 109, 2331-8		277
137	New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 274-81	5	14
136	Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment. <b>2007</b> , 70, 36-41		4
135	Immunology and immunotherapy approaches for prostate cancer. <b>2007</b> , 10, 224-36		10
134	In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma. <b>2007</b> , 42, 1396-402		9
133	Microarray Technology and Cancer Gene Profiling. <b>2007</b> ,		4
132	Current immunotherapeutic strategies in malignant melanoma. <b>2007</b> , 16, 945-73, xi		3
131	MHC class I antigens and immune surveillance in transformed cells. <b>2007</b> , 256, 139-89		105
130	Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. <i>Oncology Reports</i> , <b>2007</b> ,	3.5	2
129	Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo. <b>2007</b> , 120, 329-36		7
128	Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. <b>2007</b> , 31, 36-100		82
127	Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. <b>2007</b> , 67, 933-42		39
126	Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. <i>British Journal of Cancer</i> , <b>2007</b> , 96, 1072-82	8.7	65
125	Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 689-98	7.4	29
124	Towards progress on DNA vaccines for cancer. <b>2007</b> , 64, 2391-403		31

123	Developing effective tumor vaccines: basis, challenges and perspectives. <b>2007</b> , 1, 11-9		
122	Immune cell recruitment and cell-based system for cancer therapy. <b>2008</b> , 25, 752-68		28
121	Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer. <b>2008</b> , 56, 311-23		25
120	HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 53-61	7.4	12
119	Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity. <b>2009</b> , 18, 37-49		11
118	Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. <b>2008</b> , 15, 3538-49		17
117	Cancer immunology. <b>2008</b> , 358, 2704-15		690
116	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. <b>2008</b> , 112, 4746-54		32
115	Recent Advances in T Cell Adoptive Immunotherapy of Cancer. <b>2008</b> , 4, 1-13		1
114	Innovative Leukemia and Lymphoma Therapy. <b>2008</b> ,		
113	Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies. <b>2008</b> , 40, 89-98		11
112	Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope. <b>2008</b> , 21, 12-27		16
111	Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 458-65	5	11
110	The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides. <i>Oncology Reports</i> , <b>2008</b> ,	3.5	1
109	Impaired T lymphocyte function increases tumorigenicity and decreases tumor latency in a mouse model of head and neck cancer. <b>2009</b> , 35, 1211-21		3
108	Epigenetically regulated tumor-associated antigens in melanoma. <b>2009</b> , 4, 145-154		1
107	Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. <b>2009</b> , 182, 5498-506		25
106	Identification of a tumor associated antigen that can induce tumor specific cytotoxicity. <b>2009</b> , 8, 844-5		1



105	Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue. <b>2009</b> , 48, 391-400		30
104	Development of an artificial-antigen-presenting-cell-based assay for the detection of low-frequency virus-specific CD8(+) T cells in whole blood, with application for measles virus. <b>2009</b> , 16, 1066-73		8
103	Distinct MHC gene expression patterns during progression of melanoma. <b>2010</b> , 49, 144-54		21
102	Manganese superoxide dismutase expressed in silkworm larvae, <i>Bombyx mori</i> L enhances the NK activity and splenocyte proliferation against Sarcoma 180 tumor cells in vivo. <b>2009</b> , 36, 187-92		3
101	Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies. <b>2009</b> , 3, 173-186		
100	The new face of nucleolin in human melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 1471-80	7.4	26
99	A systematic review of humoral immune responses against tumor antigens. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 1535-44	7.4	209
98	Identification of a new broad-spectrum CD8+ T cell epitope from over-expressed antigen COX-2 in esophageal carcinoma. <b>2009</b> , 284, 55-61		9
97	Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. <b>2009</b> , 65, 1-8		25
96	Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. <b>2009</b> , 9, 579-91		12
95	Dendritic Cells. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> ,	3.2	2
94	Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. <b>2009</b> , 57, 409-23		13
93	New perspectives for melanoma immunotherapy: role of IL-12. <b>2009</b> , 9, 459-69		17
92	Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market. <b>2010</b> , 87, 401-10		25
91	Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. <b>2010</b> , 32, 1178-84		20
90	The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. <b>2010</b> , 126, 2153-63		23
89	Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server. <b>2010</b> , 1, 1097-1100		5
88	Autoantibodies for cancer detection: still cause for excitement?. <b>2010</b> , 6, 229-45		8

87	Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. <b>2010</b> , 2010, 791603		37
86	Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. <b>2010</b> , 8, 89		25
85	Cellular immunotherapy of cancer. <b>2010</b> , 651, 319-45		8
84	Immunotherapy of Cancer. <b>2010</b> ,		1
83	Cancer vaccines. Any future?. <b>2011</b> , 59, 249-59		12
82	Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. <b>2011</b> , 129, 839-46		39
81	MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. <b>2011</b> , 74, 728-43		17
80	Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. <b>2011</b> , 19, 990-9		161
79	A virus-like particle-based Epstein-Barr virus vaccine. <b>2011</b> , 85, 13105-13		58
78	MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3408-19	12.9	32
77	Peptides in melanoma therapy. <b>2012</b> , 18, 820-31		2
76	Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine. <b>2012</b> , 30, 3395-404		4
75	Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. <b>2013</b> , 35, 1373-8		25
74	Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). <i>BMC Cancer</i> , <b>2012</b> , 12, 615	4.8	47
73	Targeting HLA class I expression to increase tumor immunogenicity. <i>Tissue Antigens</i> , <b>2012</b> , 79, 147-54		40
72	Literature classification for semi-automated updating of biological knowledgebases. <i>BMC Genomics</i> , <b>2013</b> , 14 Suppl 5, S14	4.5	8
71	Therapeutic cancer vaccines. <b>2013</b> , 1018-1031		1
70	Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. <i>Clinical and Experimental Metastasis</i> , <b>2013</b> , 30, 37-45	4.7	44

69	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. <i>Expert Review of Vaccines</i> , <b>2013</b> , 12, 597-615	5.2	49
68	T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. <i>Antibodies</i> , <b>2013</b> , 2, 517-534	7	18
67	Functional OCT4-specific CD4 and CD8 T cells in healthy controls and ovarian cancer patients. <i>OncImmunology</i> , <b>2013</b> , 2, e24271	7.2	7
66	A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4228-38	12.9	77
65	Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode. <i>Frontiers in Immunology</i> , <b>2013</b> , 4, 168	8.4	21
64	Metronomic Chemotherapy. <b>2014</b> ,		2
63	In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies. <i>Cancer Science</i> , <b>2014</b> , 105, 9-17	6.9	6
62	Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma. <i>Journal of Immunology Research</i> , <b>2014</b> , 2014, 131494	4.5	16
61	Interaction of Immune and Cancer Cells. <b>2014</b> ,		
60	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1441-58	1	136
59	Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy. <i>Journal of Immunological Methods</i> , <b>2014</b> , 406, 83-103	2.5	11
58	Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients. <i>Oncology Reports</i> , <b>2014</b> , 31, 1683-90	3.5	18
57	New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles. <i>International Immunopharmacology</i> , <b>2015</b> , 26, 133-8	5.8	3
56	CD4FOXP3 T regulatory cells decrease and CD3CD8 T cells recruitment in TILs from melanoma metastases after electrochemotherapy. <i>Clinical and Experimental Metastasis</i> , <b>2016</b> , 33, 787-798	4.7	18
55	A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 1555-1564	8.7	12
54	Expression, subcellular localisation, and possible roles of dipeptidyl peptidase 9 (DPP9) in murine macrophages. <i>Cell Biochemistry and Function</i> , <b>2017</b> , 35, 124-137	4.2	1
53	Antigenic GM3 Lactone Mimetic Molecule Integrated Mannosylated Glycopeptide Nanofibers for the Activation and Maturation of Dendritic Cells. <i>ACS Applied Materials &amp; Interfaces</i> , <b>2017</b> , 9, 16035-16042	9.5	17
52	Immune targets and neoantigens for cancer immunotherapy and precision medicine. <i>Cell Research</i> , <b>2017</b> , 27, 11-37	24.7	139

51	Mannose-Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications. <i>Chemistry - an Asian Journal</i> , <b>2018</b> , 13, 3448-3459	4.5	27
50	Cancer Vaccines. <b>2018</b> , 161-184.e6		1
49	Diagnostic Value of the Survivin Autoantibody in Four Types of Malignancies. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2018</b> , 22, 384-389	1.6	5
48	Opportunities and Challenges for Antibodies against Intracellular Antigens. <i>Theranostics</i> , <b>2019</b> , 9, 7792-7806	1.8	8
47	Tumor Antigens. <b>2019</b> , 61-74		2
46	T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
45	Molecular Biochemical Aspects of Cancer. <b>2020</b> ,		0
44	The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancers. <i>Journal of Drug Targeting</i> , <b>2020</b> , 28, 1124-1136	5.4	1
43	CD8 T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , <b>2021</b> ,	36.5	40
42	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1410-1418	50.5	31
41	Peptide Vaccines.		1
40	Tinkering with nature: the tale of optimizing peptide based cancer vaccines. <i>Cancer Treatment and Research</i> , <b>2005</b> , 123, 267-91	3.5	5
39	Immune Escape. <b>2005</b> , 43-81		6
38	Tumor immunology. <i>Advances in Experimental Medicine and Biology</i> , <b>2007</b> , 593, 147-56	3.6	2
37	Immune System, Inflammation, and Essential Fatty Acids and Their Metabolites in Cancer. <b>2020</b> , 67-157		1
36	Characterization of tumor-directed cellular immune responses in humans. <b>2008</b> , 157-167		1
35	Immune Effector Cells in the Tumor Microenvironment: Their Role in Regulation of Tumor Progression. <b>2008</b> , 1-33		2
34	Monoclonal and recombinant antibodies with T cell receptor-like reactivity. <i>Recent Results in Cancer Research</i> , <b>2007</b> , 176, 229-41	1.5	2

33	Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> , 319-48	3.2	5
32	Effects of Metronomic Chemotherapy on Immunity. <b>2014</b> , 39-51		1
31	Adoptive T-Cell Immunotherapy: Perfecting Self-Defenses. <b>2014</b> , 207-232		2
30	T-cell genetic modification for re-directed tumor recognition. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , <b>2005</b> , 22, 293-324		14
29	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. <i>Journal of Immunotherapy</i> , <b>2002</b> , 25, 243-51	5	120
28	Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. <i>Annals of Surgery</i> , <b>2002</b> , 236, 785-93; discussion 793	7.8	24
27	Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 551-559	15.9	93
26	Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 551-9	15.9	51
25	Progress on new vaccine strategies for the immunotherapy and prevention of cancer. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 113, 1515-25	15.9	144
24	Molecular mimics of the tumour antigen MUC1. <i>PLoS ONE</i> , <b>2012</b> , 7, e49728	3.7	4
23	Immune Checkpoint Inhibitors: Basics and Challenges. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 3009-3025	4.3	102
22	Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 208-11	5.6	8
21	Aiming to immune elimination of ovarian cancer stem cells. <i>World Journal of Stem Cells</i> , <b>2013</b> , 5, 149-62	5.6	4
20	Tumor-associated antigens and development of immunotherapeutics strategies. <i>Biopolymers and Cell</i> , <b>2005</b> , 21, 220-229	0.3	1
19	Future Strategies in Immunotherapy. <b>2003</b> , 223-246		
18	Recent advances in the cellular immunotherapy of human cancer. <b>2003</b> , 487-498		
17	Mouse models in the recognition of tumor antigens. <b>2003</b> , 3-19		
16	Altered peptide ligands of tumor T-cell epitopes. <b>2003</b> , 97-110		

15	MHC Tetramers. <b>2004</b> , 185-198		
14	The Development and Reversal of T-Cell Tolerance in Cancer Patients Receiving Peptide-Based Vaccines. <b>2004</b> , 237-255		
13	Immunotherapy for Human Cancer. <b>2004</b> , 507-528		
12	Immunological Strategies to Fight Skin Cancer. <b>2004</b> , 745-770		
11	Tumorvakzine. <b>2006</b> , 714-724		
10	Prinzipien der Tumorimmunologie. <b>2006</b> , 101-169		
9	Therapeutic cancer vaccines. <b>2008</b> , 1135-1145		
8	Role of the Immune System in Cancer Development and Therapeutic Implications. <i>Medical Radiology</i> , <b>2009</b> , 129-145	0.2	
7	Cellular immunotherapy (CI), where have we been and where are we going?. <b>2009</b> , 505-526		
6	Dynamic Nature of Tumour-Host Interactions Within the Tumor Microenvironment. <b>2005</b> , 177-187		
5	p53-Based Immunotherapy of Cancer. <b>2006</b> , 491-505		1
4	Antigen-specific cancer vaccines. <i>Recent Results in Cancer Research</i> , <b>2007</b> , 176, 213-8	1.5	2
3	Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. <i>Cancer Research</i> , <b>2003</b> , 63, 6735-43	10.1	18
2	Immunogenicity without Immunoselection: A Mutant but Functional Antioxidant Enzyme Retained in a Human Metastatic Melanoma and Targeted by CD8+ T Cells with a Memory Phenotype. <b>2005</b> , 65, 632-640		6
1	Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer. 13,		0